InspireMD to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 14, 2021
InspireMD, a developer of the CGuard™ Embolic Prevention System for stroke prevention in carotid artery disease, will participate in the Benzinga Global Small Cap Conference on May 14, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
InspireMD, a developer of the CGuard™ Embolic Prevention System for stroke prevention in carotid artery disease, will participate in the Benzinga Global Small Cap Conference on May 14, 2021. CEO Marvin Slosman is scheduled to present at 11:10am ET and will be available for one-on-one meetings afterward. This conference offers investors an opportunity to engage with management directly. InspireMD aims to set a new industry standard with its MicroNet® technology, promoting excellent acute results and long-term stroke-free outcomes. NSPR is the company's ticker symbol on the NYSE American.
Details
News Market Reaction – NSPR
The recorded move for NSPR in the trading session of this news was -10.29%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TEL AVIV, Israel, May 06, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), announced today that management will participate at the Benzinga Global Small Cap Conference on May 14, 2021.
Chief Executive Officer Marvin Slosman will deliver his corporate presentation at 11:10am ET on May 14, 2021.
Investors can also request a one-on-one meeting with Mr. Slosman to be arranged following the conclusion of the conference.
Investors can register for the conference here:
https://www.benzinga.com/events/small-cap/global/.
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.
InspireMD’s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS and NSPR.WSB.
Investor Contacts:
Craig Shore
Chief Financial Officer
InspireMD, Inc.
888-776-6804
craigs@inspiremd.com
CORE IR
investor-relations@inspiremd.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.